Liersch-Nordqvist Annika, Fakhro Mohammed, Pierre Leif, Hlebowicz Joanna, Malmsjo Malin, Ingemansson Richard, Lindstedt Sandra
Department of Pediatric Anesthesia and Intensive Care, Skåne University Hospital, Lund, Lund University, Sweden.
Department of Cardiothoracic Surgery, Skåne University Hospital, Lund, Lund University, Sweden.
Ann Med Surg (Lond). 2017 Aug 12;22:1-6. doi: 10.1016/j.amsu.2017.08.010. eCollection 2017 Oct.
Lung transplantation is hampered by the lack of organs resulting in deaths on the waiting list. The usage of donation after circulatory death (DCD) lungs would dramatically increase donor availability. The most optimal organ preservation method, and the need for antithrombotic and fibrinolytic treatment to prevent thrombosis in the donor lungs is currently on debate. The present study investigated, in a simulated clinical DCD situation, whether the addition of alteplase in the flush-perfusion solution at the time of pulmonary graft harvesting could prevent thrombosis in the donor lung and thereby improve pulmonary graft function.
Twelve Swedish domestic pigs were randomized into two groups. All animals underwent ventricular fibrillation and were then left untouched for 1 h after declaration of death. None of the animals received heparin. The lungs were then harvested and flush-perfused with Perfadex solution and the organs were then stored at 8 °C for 4 h. In one group alteplase was added to the Perfadex solution (donation after cardiac death with alteplase (DCD-A)) and in the other, it was not (DCD). Lung function was evaluated, using ex vivo lung perfusion (EVLP), with blood gases at different oxygen levels, pulmonary vascular resistance (PVR), lung weight, and macroscopic appearance.
During EVLP, there were no significant differences between groups in PaO at any investigated FiO level (1.0, 0.5, or 0.21). At FiO 1.0, the PaO in the DCD and DCD-A was 51.7 ± 2.05 kPa and 60.3 ± 3.67 kPa, respectively (p = 0.1320). There were no significant differences between groups PVR levels, in the DCD (372 ± 31 dyne x s/cm) and in the DCD-A (297 ± 37 dyne x s/cm) groups (p = 0.1720). There was no significant difference between groups in macroscopic appearance.
All the lungs showed excellent blood gases after EVLP, and they all meet the criteria's for clinical lung transplantation. The use of alteplase did not seem to have any obvious benefit to the donor lungs in a DCD situation. The donor lungs treated with alteplas showed slightly better blood gases and slightly lower PVR compared to the group without alteplas, however the difference was not significant. DCD appears to be a safe and effective method to expand the donor pool.
肺移植因器官短缺而受阻,导致患者在等待名单上死亡。使用心脏死亡后捐赠(DCD)的肺可显著增加供体的可获得性。目前,关于最佳的器官保存方法以及是否需要抗血栓和纤维蛋白溶解治疗以预防供体肺血栓形成仍存在争议。本研究在模拟临床DCD情况下,探讨在肺移植获取时,在冲洗灌注液中添加阿替普酶是否可预防供体肺血栓形成,从而改善肺移植功能。
将12只瑞典家猪随机分为两组。所有动物均诱发心室颤动,宣布死亡后1小时内不予处理。所有动物均未接受肝素治疗。然后获取肺脏,用Perfadex溶液进行冲洗灌注,随后将器官在8℃保存4小时。一组在Perfadex溶液中添加阿替普酶(心脏死亡后使用阿替普酶捐赠(DCD-A)组),另一组不添加(DCD组)。使用体外肺灌注(EVLP)评估肺功能,检测不同氧水平下的血气、肺血管阻力(PVR)、肺重量及大体外观。
在EVLP期间,在任何研究的FiO水平(1.0、0.5或0.21)下,两组之间的PaO均无显著差异。在FiO为1.0时,DCD组和DCD-A组的PaO分别为51.7±2.05kPa和60.3±3.67kPa(p = 0.1320)。两组之间的PVR水平无显著差异,DCD组为(372±31达因×秒/厘米),DCD-A组为(297±37达因×秒/厘米)(p = 0.1720)。两组之间的大体外观无显著差异。
所有肺在EVLP后均显示出良好的血气,均符合临床肺移植标准。在DCD情况下,使用阿替普酶似乎对供体肺没有明显益处。与未使用阿替普酶的组相比,使用阿替普酶治疗的供体肺血气略好,PVR略低,但差异不显著。DCD似乎是一种安全有效的扩大供体库的方法。